CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia

T-cell prolymphocytic leukemia (T-PLL) is a poor prognostic disease with very limited options of efficient therapies. Most patients are refractory to chemotherapies and despite high response rates after alemtuzumab, virtually all patients relapse. Therefore, there is an unmet medical need for novel...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuesta-Mateos, Carlos, Fuentes, Patricia, Schrader, Alexandra, Juárez-Sánchez, Raquel, Loscertales, Javier, Mateu-Albero, Tamara, Vega-Piris, Lorena, Espartero-Santos, Marina, Marcos-Jimenez, Ana, Sánchez-López, Blanca Andrea, Pérez-García, Yaiza, Jungherz, Dennis, Oberbeck, Sebastian, Wahnschaffe, Linus, Kreutzman, Anna, Andersson, Emma I., Mustjoki, Satu, Faber, Edgar, Urzainqui, Ana, Fresno, Manuel, Stamatakis, Kostantino, Alfranca, Arantzazu, Terrón, Fernando, Herling, Marco, Toribio, María Luisa, Muñoz-Calleja, Cecilia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585232/
https://www.ncbi.nlm.nih.gov/pubmed/33110606
http://dx.doi.org/10.1186/s40364-020-00234-z

Ejemplares similares

Ejemplares similares